Arcturus Therapeutics (ARCT) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
March 1, 2021 4:01 PM ESTARCT-021 single-shot COVID-19 STARR mRNA vaccine to be advanced to Phase 3 clinical development on track to initiate Phase 3 study in Q2
ARCT-021 single shot immunogenicity profile compares favorably with new data generated from recipients of a single dose of an approved conventional mRNA vaccine
ARCT-810 mRNA therapeutic for ornithine transcarbamylase deficiency to be advanced to Phase 2 clinical development on track to file CTA for Phase 2 multiple dose study in Q2
ARCT-032 mRNA therapeutic for cystic fibrosis: completed successful pre-IND interaction with... More
